The pharmaceutical industry is the engine of the Swiss economy. If the pharmaceutical industry is struggling, Switzerland's tax revenues will decline, says René Buholzer, CEO of Interpharma, the association of research-based pharmaceutical companies. In an interview with Swiss public broadcaster SRF, Buholzer also warns that price pressure from the United States is preventing new drugs from being developed in Switzerland. SRF: Why does such a powerful industry need political support from a fe...